HUMA News & Events

Humacyte announced the presentation of research providing evidence of self-repair of the acellular tissue engineered vessel, ATEV, after cannulation for dialysis access at the Vascular Access Society of the Americas, VASA, 2026 Vascular Access for Dialysis Symposium in Salt Lake City, Utah. The presentation, titled "Self-repair of Acellular Tissue Engineered Vessels, ATEV, after Cannulation for Dialysis Access," was delivered by Maisha Clancy, MA, Process Development Engineer at Humacyte. Research demonstrated that despite repeated cannulations for dialysis access, the ATEV was observed to maintain long-term structural integrity self-repair with smooth muscle cell repopulation in explants up to 5.5 years post-implantation.

Latest data shows the largest indicative borrow rate increases among liquid option names include: Kodiak AI, Inc. Common Stock (KDK) 210.02% +48.07, Eagle Nuclear Energy Corp (NUCL) 147.89% +1.58, Draganfly (DPRO) 12.06% +0.92, Rezolve AI Ltd (RZLV) 21.96% +0.92, Humacyte (HUMA) 22.50% +0.83, Innoviz (INVZ) 3.20% +0.50, Angion Biomedica Corp (ELTX) 5.12% +0.50, Prairie Operating Co (PROP) 5.08% +0.34, Energy Transfer (ET) 2.22% +0.34, and Quantum Si (QSI) 1.50% +0.33.

Humacyte announced that Symvess is now under contract with the with Strategic Acquisition Center of the U.S. Department of Veterans Affairs. The SAC contract makes Symvess more easily accessible to 170 VA hospitals as the SAC system is the preferred and primary sourcing vehicle for VA hospitals. "We are pleased that Symvess is now under contract with the Strategic Acquisition Center, making the first-in-class product accessible to healthcare professionals treating military veterans," said Dr. Laura Niklason, President and CEO of Humacyte, Inc. "SAC is the preferred sourcing vehicle for the VA, and we anticipate that the SAC SING contract will expedite our ability to respond to interest from surgeons operating in the VA system."